|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.070 USD | +3.88% |
|
-2.73% | -35.93% |
| 07-14 | Lineage Cell Therapeutics, Inc. - Special Call | |
| 07-13 | Lineage Cell Therapeutics Provides Update On COR1 Cell Therapy Program For Corneal Endothelial Disease | CI |
Company Valuation: Lineage Cell Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 256.8 | - | - |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -36.55% | - | - |
| Enterprise Value (EV) | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 256.8 | 256.8 | 256.8 |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -36.55% | 0% | 0% |
| P/E | -9.42x | -7.8x | -9.08x | -5.58x | -5.96x | -15.6x | -11.7x | 89.2x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.5x | 0.2x | -0x | 0.2x | -0.4x | -1x |
| Capitalization / Revenue | 95.1x | 13.5x | 21.3x | 11.7x | 27.8x | 14.3x | 14.2x | 4.31x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 14.3x | 14.2x | 4.31x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -10.4x | -9.95x | -8.44x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -10.5x | -10.2x | 33.7x |
| EV / FCF | - | 0x | -0x | -0x | -0x | -27.6x | -28.9x | 70.3x |
| FCF Yield | - | 0.32% | -15.3% | -21.4% | -4.8% | -3.62% | -3.47% | 1.42% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 | -0.0686 | -0.0914 | 0.012 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.341 | 14.7 | 8.945 | 9.499 | 14.56 | 17.94 | 18.14 | 59.63 |
| EBITDA 1 | -48.34 | -21.79 | -24.04 | -20.87 | -35.92 | -24.75 | -25.8 | -30.42 |
| EBIT 1 | -49.21 | -22.52 | -24.73 | -21.48 | -36.62 | -24.41 | -25.3 | 7.618 |
| Net income 1 | -43.02 | -26.27 | -21.49 | -18.61 | -63.53 | -24.11 | -31.83 | 7.158 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 2.450 | 1.170 | 1.090 | 0.502 | 1.670 | 1.070 | 1.070 | 1.070 |
| Nbr of stocks (in thousands) | 168,558 | 169,976 | 174,987 | 220,416 | 242,328 | 249,298 | - | - |
| Announcement Date | 10/03/22 | 09/03/23 | 07/03/24 | 10/03/25 | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.02x | - | - | - | 257M | |
| 32.79x | 5.87x | 17.42x | 1% | 47.74B | |
| -23.47x | 352.2x | -21.51x | -.--% | 39.98B | |
| 48.32x | 4.93x | 31.87x | -.--% | 36.23B | |
| 25.95x | 2.85x | 12.32x | -.--% | 35.59B | |
| 27.91x | 7.98x | 19.84x | 0.43% | 27.91B | |
| 33.62x | 5.49x | 25.05x | -.--% | 16.45B | |
| 22.1x | 1.97x | 8.54x | 1.19% | 13.21B | |
| 23.86x | 1.9x | 11.51x | -.--% | 12.93B | |
| Average | 19.56x | 47.90x | 13.13x | 0.33% | 25.59B | |
| Weighted average by Cap. | 22.71x | 65.23x | 12.14x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LCTX Stock
- Valuation Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
